Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05334927
Other study ID # KY2022-tt02
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date August 29, 2022
Est. completion date December 31, 2032

Study information

Verified date June 2022
Source Beijing Tiantan Hospital
Contact Yong Gang Wang, Doctor
Phone 15010066622
Email w100yg@163.com
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

It is planned to include 10000 patients. In the China HeadAche DIsorders RegiStry CHAIRS), patients aged over 12 years with primary headache and medication-overuse headache(MOH) were collected. The biomarkers, imaging features, cognition, genetic characteristics, ocial and demographic data, medical data, therapeutics used, and outcome of headache-related diseases were studied, and long-term follow-up was planned.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 10000
Est. completion date December 31, 2032
Est. primary completion date December 31, 2031
Accepts healthy volunteers No
Gender All
Age group 12 Years and older
Eligibility Inclusion Criteria: 1. Age = 12 years old,Any gender; 2. The first onset age of primary headache was less than 50 years old(Age <65 years at first diagnosis of chronic migraine); 3. patients with primary headache (migraine, tension headache and other types of primary headache) or primary headache complicated with MOH according to ICHD-3; 4. Sign the informed consent form. Exclusion Criteria: 1. According to the ICHD-3 diagnostic criteria, there are still headaches directly related to secondary factors (except drug overuse) at the time of enrollment; 2. Those who cannot be diagnosed as primary headache or primary headache combined with medication overuse headache according to ICHD-3; 3. According to DSM-V diagnostic criteria, patients with severe mental diseases (such as schizophrenia, mental disorders associated with mental retardation, etc.); 4. Patients with severe organic diseases, such as malignant tumors, and the expected survival time is less than 1 year; 5. Pregnant,planning pregnancy or Lactating women; 6. Subjects participating in other clinical trials; 7. Unable to cooperate to complete the follow-up due to geographical or other reasons

Study Design


Intervention

Behavioral:
Medicine Overuse Headache/New Daily Persistent Headache
At the end of the 24th month visit, the patient is free to choose whether to conduct a face-to-face visit once a year until death.
Chronic Migraine
long-term follow-up
Patients with other types of primary headache
No collection Brain imaging?Cognitive function test?Biological sample

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Beijing Tiantan Hospital

Outcome

Type Measure Description Time frame Safety issue
Primary Headache Days The number of days of headache is the number of days in which headache occurs. long term: 10 years
Primary MRI change Patients will accept MRI scans will be done at baseline and once per year. long term: 10 years
Primary Genetic analysis of familial headache Blood samples will be collected from all participants who consent to participate in the study, for the purposes of genetic analysis of familial headache. 1 year
Primary Montreal Cognitive Assessment (MoCA) The Montreal Cognitive Assessment (MoCA) will be used to assess changes in cognitive functions. long term: 10 years
Primary Mini-Mental State Exam (MMSE) The Mini-Mental State Examination (MMSE) is a 30-point questionnaire that is used in clinical and research settings to assess cognitive function. long term: 10 years
Primary Migraine Disability Assessment (MIDAS) The MIDAS is a 7-item questionnaire designed to quantify headache-related disability over a 3- month period. The MIDAS score is the sum of missed work or school days, days at work or school plus days of household work where productivity was reduced by half or more, missed household work days, and missed non-work activity days due to headaches in the last 3 months. long term: 10 years
Primary Generalized Anxiety Disorder (GAD-7) GAD-7 is a proven, self-administered and concise tool for screening and diagnosing mental health disorders, which has been tested in the field in office practice. The GAD-7 scale score ranges from 0 to 21. long term: 10 years
Primary Patient Health Questionnaire (PHQ)-9 The PHQ-9 is the depression module, which scores each of the 9 DSM-IV criteria as "0" (not at all) to "3" (nearly every day). A PHQ-9 score total of 0-4 points equals "normal" or minimal depression. Scoring between 5-9 points indicates mild depression, 10-14 points indicates moderate depression, 15-19 points indicates moderately severe depression, and 20 or more points indicates severe depression. long term: 10 years
Secondary Social and demographic data, medical history Social and demographic data, medical and medication history will be collected at initial screening. long term: 10 years
Secondary Use of Rescue Medication Frequency of Rescue medication will be collected by eDiary. long term: 10 years
Secondary Moderate / Severe Headache Days Moderate / severe headache days are defined as a day in which moderate or severe pain persists for at least 4 hours, or headache lasts for one day after successful medication for acute headache. These definitions allow the use of relatively simple headache diaries. Subjects were required to indicate whether headache was present (yes / no), peak (mild / moderate / severe) severity and duration (< 4h or 4h), type of acute drug intake, and response to treatment should also be recorded. long term: 10 years
Secondary Pain severity Pain severity were captured through Visual analogue scale (VAS) for pain, a continuous scale comprised of a horizontal line, anchored by "no pain" (score of 0) and "worst imaginable pain" (score of 10). long term: 10 years
Secondary MEG Patients will accept MEG. long term: 10 years
Secondary PET Patients will accept PET scan. long term: 10 years
Secondary EEG Patients will accept EEG scan. long term: 10 years
Secondary Proteomics Blood, urine and Cerebrospinal fluid samples will be collected from all participants who consent to participate in the study, for the purposes of Proteomics at baseline and month 12. 1 year
Secondary Microbiome Saliva samples will be collected from all participants who consent to participate in the study, for the purposes of Microbiome at baseline and month 12. 1 year
Secondary Headache Impact Test (HIT-6) The HIT-6 is a 6-question assessment used to measure the impact headaches have on a participant's ability to function on the job, at school, at home, and in social situations. It assesses the effect that headaches have on normal daily life and the participant's ability to function. long term: 10 years
Secondary European Quality of Life 5 Dimensions 3 Level Version (EQ-5D-3L) EQ-5D-3L is a generic instrument for use as a measure of health status. The EQ-5D-3L consists of 2 components-the EQ-5D descriptive system and the EQ VAS. The descriptive system comprises of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). The respondent is asked to indicate his/her health state by ticking (or placing a cross) in the box against the most appropriate statement in each of the 5 dimensions.
The EQ VAS records the respondent's self-rated health on a vertical, VAS where the endpoints are labelled "Best imaginable health state" and "Worst imaginable health state." The scoring range of the EQ VAS is from 0 (worst imaginable health) to 100 (best imaginable health).
long term: 10 years
Secondary Migraine Specific Quality of Life Questionnaire, Version 2.1 (MSQ v2.1) The MSQ v2.1 is a 14-item questionnaire designed to measure health-related quality-of-life impairments attributed to migraine in the past 4 weeks. It is divided into 3 domains: Role Function Restrictive assesses how migraines limit one's daily social and work-related activities; Role Function Preventive assesses how migraines prevent these activities; and the Emotional Function domain assesses the emotions associated with migraines. long term: 10 years
Secondary Pittsburgh Sleep Quality Index (PSQI) The Pittsburgh Sleep Quality Index (PSQI) is an effective instrument used to measure the quality and patterns of sleep. long term: 10 years
Secondary Columbia-Suicide Severity Rating Scale C-SSRS will be administered to study subjects at each study visit to assess possible suicidal ideation and behavior. Reports of suicidal ideation with intent to act (endorse item 4 or 5) and reports of actual, aborted, or interrupted suicide attempts or a behavior preparatory for making an attempt indicate subjects at high risk for suicide. long term: 10 years
See also
  Status Clinical Trial Phase
Completed NCT06192173 - Patent Foramen Ovale Closure in Migraine
Completed NCT05525611 - Cabergoline as a Preventive Treatment for Chronic Migraine N/A
Recruiting NCT03832998 - Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine Phase 3
Enrolling by invitation NCT04196933 - Analysis of Vestibular Compensation Following Clinical Intervention for Vestibular Schwannoma N/A
Not yet recruiting NCT06428838 - Eptinezumab as an Adjunct to Standard of Care for Migraine in an Acute Emergency Context Phase 3
Completed NCT06304675 - Manageable Environmental Factors in Migraine
Completed NCT04084314 - Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label Study Phase 4
Recruiting NCT05517200 - Pilot Study for a Machine Learning Test for Migraine
Completed NCT04179474 - Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With Migraine Phase 1
Recruiting NCT04603976 - Registry for Migraine - Clinical Core Phase 4
Completed NCT03597529 - CHOCOlate MeLatonin for AdolescenT MigrainE Phase 2
Completed NCT04197349 - Safety, Tolerability and Pharmacokinetics of ALD1910 in Healthy Men and Woman Phase 1
Recruiting NCT05891808 - miR-155 Expression in Episodic and Chronic Migraine
Active, not recruiting NCT05064371 - Long-Term Extension Study With Eptinezumab as Preventive Treatment in Participants With Migraine in Japan Phase 3
Suspended NCT04069572 - Vibratory Stimulation for the Treatment of Chronic Pain N/A
Not yet recruiting NCT04859374 - Chronic Pain and Conditioned Pain Modulation After on Line-behavioral Approach N/A
Not yet recruiting NCT03083860 - Evaluation of Migraine Management Mobile App Combined With Electrophysiological Measurements for Identification of Migraine Attack Risk and Beneficial Preventive Actions. N/A
Completed NCT02905227 - A Study of the Pulmonary Safety and Pharmacokinetics of Zolmitriptan Inhalation Powder Phase 1
Enrolling by invitation NCT02532023 - The Combined Effects of omega3 Fatty Acids and Curcumin Supplementation on Inflammatory and Endothelial Factors in Migraine Patients Phase 4
Completed NCT02108678 - One-Day Intervention for Depression and Impairment in Migraine Patients N/A